Halil I. Ciftci

1.3k total citations
51 papers, 922 citations indexed

About

Halil I. Ciftci is a scholar working on Organic Chemistry, Molecular Biology and Toxicology. According to data from OpenAlex, Halil I. Ciftci has authored 51 papers receiving a total of 922 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Organic Chemistry, 21 papers in Molecular Biology and 10 papers in Toxicology. Recurrent topics in Halil I. Ciftci's work include Synthesis and biological activity (19 papers), Bioactive Compounds and Antitumor Agents (10 papers) and Cancer therapeutics and mechanisms (7 papers). Halil I. Ciftci is often cited by papers focused on Synthesis and biological activity (19 papers), Bioactive Compounds and Antitumor Agents (10 papers) and Cancer therapeutics and mechanisms (7 papers). Halil I. Ciftci collaborates with scholars based in Japan, Türkiye and Egypt. Halil I. Ciftci's co-authors include Mikako Fujita, Masami Otsuka, Mohamed O. Radwan, Belgin Sever, Mehlika Dilek Altıntop, Ahmet Özdemır, Hiroshi Tateishi, Ryoko Koga, Taha F. S. Ali and Amaç Fatih Tuyun and has published in prestigious journals such as Scientific Reports, FEBS Letters and International Journal of Molecular Sciences.

In The Last Decade

Halil I. Ciftci

48 papers receiving 914 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Halil I. Ciftci Japan 19 500 397 180 109 55 51 922
Belgin Sever Türkiye 23 951 1.9× 631 1.6× 99 0.6× 187 1.7× 64 1.2× 79 1.6k
Roberta Rocca Italy 21 269 0.5× 689 1.7× 34 0.2× 74 0.7× 35 0.6× 54 1.1k
Randall W. Hungate United States 22 748 1.5× 643 1.6× 36 0.2× 141 1.3× 23 0.4× 51 1.4k
Paul Tunnah France 4 443 0.9× 626 1.6× 57 0.3× 323 3.0× 61 1.1× 5 1.1k
Julie A. Spicer New Zealand 18 454 0.9× 413 1.0× 98 0.5× 113 1.0× 12 0.2× 39 1.0k
Xuewei Wu China 15 463 0.9× 693 1.7× 74 0.4× 212 1.9× 70 1.3× 28 1.3k
Hui-Yi Shiao Taiwan 12 304 0.6× 271 0.7× 18 0.1× 114 1.0× 66 1.2× 13 626
Jelena Dinić Serbia 19 168 0.3× 671 1.7× 35 0.2× 219 2.0× 66 1.2× 65 1.1k
Dean Stamos United States 21 598 1.2× 704 1.8× 47 0.3× 209 1.9× 10 0.2× 30 1.4k
Jean‐Marc Barret France 20 225 0.5× 905 2.3× 104 0.6× 375 3.4× 64 1.2× 43 1.3k

Countries citing papers authored by Halil I. Ciftci

Since Specialization
Citations

This map shows the geographic impact of Halil I. Ciftci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Halil I. Ciftci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Halil I. Ciftci more than expected).

Fields of papers citing papers by Halil I. Ciftci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Halil I. Ciftci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Halil I. Ciftci. The network helps show where Halil I. Ciftci may publish in the future.

Co-authorship network of co-authors of Halil I. Ciftci

This figure shows the co-authorship network connecting the top 25 collaborators of Halil I. Ciftci. A scholar is included among the top collaborators of Halil I. Ciftci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Halil I. Ciftci. Halil I. Ciftci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sever, Belgin, Canan Sevimli-Gür, Mustafa Can, et al.. (2025). Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds. Pharmaceuticals. 18(2). 270–270. 9 indexed citations
2.
3.
4.
Sever, Belgin, Masami Otsuka, Mikako Fujita, & Halil I. Ciftci. (2024). A Review on FDA Approved Anti-HIV-1 Drugs, Anti-Gag Compounds and Potential Strategies for HIV-1 Eradication. Preprints.org. 7 indexed citations
5.
Sever, Belgin, Abdulilah Ece, Hiroshi Tateishi, et al.. (2023). Structural Characterization of TRAF6 N-Terminal for Therapeutic Uses and Computational Studies on New Derivatives. Pharmaceuticals. 16(11). 1608–1608. 4 indexed citations
6.
7.
Özdemır, Ahmet, Halil I. Ciftci, Belgin Sever, et al.. (2022). A New Series of Indeno[1,2-c]pyrazoles as EGFR TK Inhibitors for NSCLC Therapy. Molecules. 27(2). 485–485. 11 indexed citations
8.
Ali, Taha F. S., Halil I. Ciftci, Mohamed O. Radwan, et al.. (2022). Discovery of Azaindolin-2-One as a Dual Inhibitor of GSK3β and Tau Aggregation with Potential Neuroprotective Activity. Pharmaceuticals. 15(4). 426–426. 6 indexed citations
9.
Sever, Belgin & Halil I. Ciftci. (2022). Evaluation of anti-glioma effects of benzothiazoles as efficient apoptosis inducers and DNA cleaving agents. Molecular and Cellular Biochemistry. 478(5). 1099–1108. 3 indexed citations
10.
Sever, Belgin, Halil I. Ciftci, Hasan DeMi̇rci̇, et al.. (2022). Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences. 23(5). 2400–2400. 49 indexed citations
11.
Ciftci, Halil I., Mohamed O. Radwan, Belgin Sever, et al.. (2021). EGFR-Targeted Pentacyclic Triterpene Analogues for Glioma Therapy. International Journal of Molecular Sciences. 22(20). 10945–10945. 27 indexed citations
12.
Bayrak, Nilüfer, Halil I. Ciftci, Mahmut Yıldız, et al.. (2021). Structure based design, synthesis, and evaluation of anti-CML activity of the quinolinequinones as LY83583 analogs. Chemico-Biological Interactions. 345. 109555–109555. 24 indexed citations
13.
Sever, Belgin, Mehlika Dilek Altıntop, Ahmet Özdemır, et al.. (2020). In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors. Molecules. 25(21). 5190–5190. 45 indexed citations
14.
Altıntop, Mehlika Dilek, Belgin Sever, Ahmet Özdemır, et al.. (2020). A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors. Anti-Cancer Agents in Medicinal Chemistry. 21(9). 1099–1109. 15 indexed citations
15.
Ciftci, Halil I., Mustafa Can, Doha El‐Sayed Ellakwa, et al.. (2020). Anticancer activity of Turkish marine extracts: a purple sponge extract induces apoptosis with multitarget kinase inhibition activity. Investigational New Drugs. 38(5). 1326–1333. 21 indexed citations
16.
Ciftci, Halil I., Raymond G. Sierra, Chun Hong Yoon, et al.. (2019). Serial Femtosecond X-Ray Diffraction of HIV-1 Gag MA-IP6 Microcrystals at Ambient Temperature. International Journal of Molecular Sciences. 20(7). 1675–1675. 7 indexed citations
17.
Sever, Belgin, Mehlika Dilek Altıntop, Mohamed O. Radwan, et al.. (2019). Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. European Journal of Medicinal Chemistry. 182. 111648–111648. 96 indexed citations
18.
Bayrak, Nilüfer, Hatice Yıldırım, Mahmut Yıldız, et al.. (2019). Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents. Bioorganic Chemistry. 92. 103255–103255. 37 indexed citations
19.
Ali, Taha F. S., Halil I. Ciftci, Mohamed O. Radwan, et al.. (2019). New SIRT2 inhibitors: Histidine-based bleomycin spin-off. Bioorganic & Medicinal Chemistry. 27(9). 1767–1775. 17 indexed citations
20.
Tateishi, Hiroshi, Kazuaki Monde, Ryoko Koga, et al.. (2017). A clue to unprecedented strategy to HIV eradication: “Lock-in and apoptosis”. Scientific Reports. 7(1). 8957–8957. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Belgin Sever Breakdown of academic impact, for papers by Roberta Rocca Breakdown of academic impact, for papers by Randall W. Hungate Breakdown of academic impact, for papers by Paul Tunnah Breakdown of academic impact, for papers by Julie A. Spicer Breakdown of academic impact, for papers by Xuewei Wu Breakdown of academic impact, for papers by Hui-Yi Shiao Breakdown of academic impact, for papers by Jelena Dinić Breakdown of academic impact, for papers by Dean Stamos Breakdown of academic impact, for papers by Jean‐Marc Barret
Rankless by CCL
2026